BMI
Badger Meter, Inc.
BMI trails on the overall score without a compensating advantage in the available component scores.
MSFT
Microsoft Corporation
MSFT has the edge over BMI overall, supported by stronger fundamentals and stronger modeled upside.
BMI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
BMI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
BMI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 32x | $154 | — |
| Current | 35x | $154 | — |
| Cheap | 37x | $160 | +4.3% |
| Fair | 49x | $212 | +38% |
| Expensive | 55x | $238 | +55% |
Historical ranges are pointers, not guarantees.
BMI's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 32x next year's earnings.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT has the edge over BMI in the historical PE scenario, which offers more potential upside but is not a forecast.
BMI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Moderate |
Analysts expect BMI's earnings to grow, with its revenue and profitability holding steady.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
MSFT has the edge over BMI on the outlook, with more favorable revenue expectations.
BMI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.87 | +12% |
| Q3 2026 | $4.33 | -7.9% |
| Q2 2026 | $4.28 | -6.8% |
| Q1 2026 | $4.43 | -2.4% |
| Q4 2025 | $4.80 | +13% |
| Q3 2025 | $4.70 | +17% |
| Q2 2025 | $4.59 | +20% |
| Q1 2025 | $4.54 | +31% |
| Q4 2024 | $4.23 | +35% |
BMI earned $4.33 per share over the past year, down 7.9% from the year before.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT has the edge over BMI on earnings, with more consistent year-over-year improvement.
BMI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $235.9M | +0.1% |
| Q2 2026 | $222.3M | -6.6% |
| Q1 2026 | $202.3M | -9% |
| Q4 2025 | $220.7M | +7.6% |
| Q3 2025 | $235.7M | +13% |
| Q2 2025 | $238.1M | +9.9% |
| Q1 2025 | $222.2M | +13% |
| Q4 2024 | $205.2M | +12% |
BMI's revenue grew through 2024 and has held roughly level since: $236M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +0.7 points |
| Q2 2026 | 18% | -1.1 points |
| Q1 2026 | 17% | -4.8 points |
| Q4 2025 | 20% | +0.4 points |
| Q3 2025 | 20% | +0.1 points |
| Q2 2025 | 19% | -0.3 points |
| Q1 2025 | 22% | +3.6 points |
| Q4 2024 | 19% | +1.5 points |
BMI's operating margin was 20% last quarter, up 0.7 points from the same quarter a year ago, near the top of its range since 2019.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT has the edge over BMI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over BMI on profitability, with a higher operating margin.
BMI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $40.3M | -16% |
| Q2 2026 | $21.9M | -46% |
| Q1 2026 | $29.5M | -2% |
| Q4 2025 | $50.8M | +7.1% |
| Q3 2025 | $48.2M | +15% |
| Q2 2025 | $40.6M | +19% |
| Q1 2025 | $30.1M | +60% |
| Q4 2024 | $47.4M | +32% |
BMI has the edge over MSFT on cash flow, with more consistent year-over-year improvement.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT's free cash flow has been positive every quarter for seven years: $60B over the past year, down 23% from the year before.
BMI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -271K shares |
| 1 year | -2.4% | -712K shares |
| 3 years | -1.9% | -550K shares |
| 5 years | -1.3% | -395K shares |
BMI has the edge over MSFT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $55.5M |
| Q2 2026 | $25.3M |
| Q1 2026 | $38.2M |
| Q4 2022 | — |
| Q3 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q4 2020 | $182,000 |
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has 7.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
BMI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.4x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.2x | Net Cash |
| Q3 2025 | -1.1x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -0.7x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
BMI has the edge over MSFT on leverage, with a lower net debt burden relative to earnings.
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
BMI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 74.5 | Neutral |
BMI's weekly RSI is 58 (neutral) and its Stochastic is 75 (neutral).
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
BMI PE vs Technology Sector
| Metric | BMI | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 28x | 27% above |
| PE % | 14 | 35 | 21 pts below |
BMI is trading at 35x earnings, a 27% premium to the Technology sector's median of 28x.
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT has the edge over BMI on valuation relative to its sector.
BMI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $140.8 | 9.1% above |
| 20 week MA | $137.7 | 12% above |
| 50 week MA | $144.3 | 6.4% above |
| 100 week MA | $174.9 | 12% below |
| 200 week MA | $169.6 | 9.5% below |
BMI has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 9.5% below its 200-week average.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT has the edge over BMI on trend strength, trading above more of its moving averages.
BMI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.1 | $93.7 | +42% |
| 2021 | $93.7 | $105.2 | +12% |
| 2022 | $105.2 | $109.6 | +4.2% |
| 2023 | $109.6 | $154.4 | +41% |
| 2024 | $154.4 | $215.5 | +40% |
| 2025 | $215.5 | $180.8 | -16% |
| 2026 YTD | $180.8 | $153.6 | -15% |
BMI has finished higher in five of the last six years. It's down 15% so far in 2026.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has the edge over BMI on returns for 2026, with the stronger performance.